Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)
{{output}}
Background The PARP inhibitor olaparib has shown acceptable toxicity at doses of up to 400 mg twice daily (bid; capsule formulation) with encouraging signs of antitumor activity. Based on its mode of action, olaparib may sensitize tumor cells to DNA-damaging a... ...
